Bioequivalence of Rivaroxaban Hard Capsules vs. Film-Coated Tablets in Healthy White Volunteers

Autor: Agnieszka Gierczak-Pachulska, Michał Kaza, Katarzyna Jarus-Dziedzic, Olga Czerepow-Bielik, Agnieszka Segiet-Święcicka, Grzegorz Huszcza, Katarzyna Sidoruk, Daniel Rabczenko, Piotr J. Rudzki

Publikováno v: Acta Poloniae Pharmaceutica, Vol 81, Iss 1, Pp 97-108 (2024)

Rivaroxaban is an oral anticoagulant that is a selective, direct factor Xa inhibitor. It is used to prevent thrombotic events of atherosclerotic etiology and to prevent stroke and peripheral embolism in adult patients with nonvalvular atrial fibrilla

Externí odkaz: https://doaj.org/article/316b5d2cc8424ab39a49b99e3bb9ff89

Replicates Number for Drug Stability Testing during Bioanalytical Method Validation—An Experimental and Retrospective Approach

Autor: Elżbieta Gniazdowska, Wojciech Goch, Joanna Giebułtowicz, Piotr J. Rudzki

Publikováno v: Molecules, Vol 27, Iss 2, p 457 (2022)

Background: The stability of a drug or metabolites in biological matrices is an essential part of bioanalytical method validation, but the justification of its sample size (replicates number) is insufficient. The international guidelines differ in re

Externí odkaz: https://doaj.org/article/e6a4e05174b947328918eb428326966b

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combined Protein and Alkaloid Research of Chelidonium majus Latex Reveals CmMLP1 Accompanied by Alkaloids with Cytotoxic Potential to Human Cervical Carcinoma Cells

Autor: Elżbieta Urszula Stolarczyk, Robert Nawrot, Jacek Musijowski, Anna Goździcka-Józefiak, Piotr J. Rudzki, Oskar Musidlak, Alicja Warowicka, Katarzyna Magdalena Dolata

Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 11838, p 11838 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 21

Chelidonium majus L. is a latex-bearing plant used in traditional folk medicine to treat human papillomavirus (HPV)-caused warts, papillae, and condylomas. Its latex and extracts are rich in many low-molecular compounds and proteins, but there is lit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe13bcdd9518431124d359e8c9d2911
https://www.mdpi.com/1422-0067/22/21/11838

761-P: Safety and Pharmacokinetic Study of GPR40 Agonist (CPL207280) after a Single Dose in Healthy Subjects

Autor: Maciej Wieczorek, Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, Agnieszka Gierczak-Pachulska, Katarzyna Bazydlo-Guzenda

Publikováno v: Diabetes. 70

Activation of GPR40 (G-protein coupled receptor 40) in pancreatic β-cells may improve glycaemic control in type 2 diabetes (T2D) patients through enhancement of glucose-stimulated insulin secretion (GSIS). Here we present phase I an open label, dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75efd9bc7868cfd71884ec874298ca33
https://doi.org/10.2337/db21-761-p